Roche Continuous Epoetin CERA BLA Submitted For Dosing Every Four Weeks
This article was originally published in The Pink Sheet Daily
Executive Summary
CERA will have an estimated user fee date of mid February under standard review for treatment of renal anemia.
You may also be interested in...
Roche’s Mircera BLA Set Back Three Months For FDA Review Of New Data
Delay could affect Amgen’s timeline for a potential filing of a preliminary injunction in its case against Roche, slated for trial in September.
Roche’s Mircera BLA Set Back Three Months For FDA Review Of New Data
Delay could affect Amgen’s timeline for a potential filing of a preliminary injunction in its case against Roche, slated for trial in September.
Roche Invests In Xenon’s Novel Anemia Treatment Platform
Two-year licensing, equity investment deal with the Canadian drug discovery firm will explore protein modulators to treat anemia of inflammation.